Neo-wt-RAS in ctDNA: Is It Worth Using Anti-EGFR Therapies?

Pasquale F Innominato1, Abdoulaye Karaboué1, Francis A Lévi1

  • 1Pasquale F. Innominato, MD, PhD, North Wales Cancer Centre, Ysbyty Gwynedd, Betsi Cadwaladr University Health Board, Bangor, United Kingdom, Cancer Chronotherapy Team, Division of Biomedical Sciences, Medical School, Warwick University, Coventry, United Kingdom; Abdoulaye Karaboué, MD, PhD, UPR "Chronotherapy, Cancer and Transplantation," Medical School, Paris-Saclay University, Villejuif, France, Medical Oncology Unit, GHT Paris Grand Nord-Est, Le Raincy-Montfermeil, Montfermeil, France; and Francis A. Lévi, MD, PhD, Cancer Chronotherapy Team, Division of Biomedical Sciences, Medical School, Warwick University, Coventry, United Kingdom, UPR "Chronotherapy, Cancer and Transplantation," Medical School, Paris-Saclay University, Villejuif, France, Gastro-intestinal and Medical Oncology Service, Paul Brousse Hospital, Villejuif, France.

JCO Precision Oncology
|November 7, 2024
PubMed
Abstract

No abstract available in PubMed .